AmVac AG

Info

The mission of AmVac is the development and commercialization of innovative vaccines that target major unmet medical needs.

Geschichte

AmVac AG is a privately held vaccine developer creating new opportunities for the treatment and prevention of widespread infections and urogenital conditions. With a diverse portfolio of proprietary technologies and novel vaccine candidates, the company is set to become a major, highly innovative player in the rapidly growing global vaccine market and a premier licensing partner to the international pharmaceutical industry.

With a high-potential lead product that has already gained regulatory approval in some markets and two additional proprietary vaccine platforms with promising pipelines, AmVac has a uniquely low-risk profile within the biotech industry, with thepotential for very high returns even in the near term. In addition to growing trade sales, AmVac expects to receive substantial out-licensing fees in each of the next three years. The cash-rich balance sheet will be able to provide above-average returns to shareholders, while also financing furtherproduct development initiatives.